Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.93 USD
Change Today +0.04 / 0.31%
Volume 98.0K
GNCA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

genocea biosciences inc (GNCA) Snapshot

Open
$13.01
Previous Close
$12.89
Day High
$13.61
Day Low
$12.85
52 Week High
06/23/14 - $23.99
52 Week Low
01/22/15 - $6.15
Market Cap
312.2M
Average Volume 10 Days
118.2K
EPS TTM
$-2.34
Shares Outstanding
24.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOCEA BIOSCIENCES INC (GNCA)

Related News

No related news articles were found.

genocea biosciences inc (GNCA) Related Businessweek News

No Related Businessweek News Found

genocea biosciences inc (GNCA) Details

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase II trials to treat genital herpes infections. It is also developing GEN-004, a Phase II vaccine for the prevention of pneumococcal infections; GEN-001 that is in pre-clinical product candidate for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-2 prophylaxis; and GEN-005 that is in research stage for treating malaria prophylaxis. The company was founded in 2006 and is based in Cambridge, Massachusetts.

57 Employees
Last Reported Date: 02/27/15
Founded in 2006

genocea biosciences inc (GNCA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $393.6K
Chief Financial Officer and Secretary
Total Annual Compensation: $285.2K
Chief Medical Officer
Total Annual Compensation: $366.1K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Compensation as of Fiscal Year 2014.

genocea biosciences inc (GNCA) Key Developments

Genocea Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 09:20 AM

Genocea Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 09:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Jonathan Poole, Chief Financial Officer.

Genocea Biosciences, Inc. Appoints Michael Higgins as Directors

Genocea Biosciences, Inc. announced that Michael Higgins has joined the company's board of directors. Mr. Higgins is an experienced biotechnology executive and is currently entrepreneur-in-residence at Polaris Venture Partners. He previously served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals from 2003 to 2014.

Genocea Biosciences, Inc. Reports Unaudited Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Genocea Biosciences, Inc. reported unaudited financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported grant revenue of $0.308 million against $0.020 million a year ago. Loss from operations was $10.926 million against $6.169 million a year ago. Net loss was $11.650 million against $6.346 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $0.66 against $22.50 a year ago. For the year, the company reported grant revenue of $0.308 million against $0.731 million a year ago. Loss from operations was $33.166 million against $19.925 million a year ago. Net loss was $35.296 million against $20.806 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $2.27 against $75.46 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNCA:US $12.93 USD +0.04

GNCA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $20.00 USD +0.53
Dynavax Technologies Corp $23.48 USD -0.10
Eurocine Vaccines AB kr2.73 SEK -0.05
GenVec Inc $2.81 USD -0.06
Inovio Pharmaceuticals Inc $10.32 USD +0.28
View Industry Companies
 

Industry Analysis

GNCA

Industry Average

Valuation GNCA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 740.6x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 820.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOCEA BIOSCIENCES INC, please visit www.genocea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.